Drug Trial Radar · NCT07766980
Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Jul 27, 2026
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- University of FloridaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pilot study will investigate the potential efficacy of VM100, a nutritional supplement specifically formulated for patients with DMD, on quality of life and physical symptoms. Twenty patients (aged 8 an over) will be enrolled to undergo a 10-week placebo-controlled intervention with VM100. Outcomes will include validated questionnaires and qualitative interview to assess impact on mental, cognitive and mood related measures, as well as endurance and fatigue).
Conditions
- Duchenne Muscular Dystrophy
- Duchenne Disease
- Muscular Dystrophy in Children
- DMD
- Muscular Dystrophy
Interventions
VM100 Nutritional SupplementDrug
VM100 is an investigational dietary supplement formulated specifically for individuals with Duchenne muscular dystrophy. It contains ten naturally derived ingredients formulated using a proprietary technology to enhance bioavailability. The supplement is intended to support mitochondrial function, reduce inflammation and oxidative stress, improve cognitive function and mood, and promote overall quality of life. Participants will self-administer the supplement orally twice daily during the intervention period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in DMD Quality of Life Physical Symptoms Domain ScoreTime frame: Baseline, Weeks 2, 6, 8, and 10
- Changes in Mental Wellbeing assessed Warwick-Edinburgh Mental Well-being Scale ScoreTime frame: Baseline, Weeks 2, 6, 8, and 10
- Changes in Quality of Life assessed by PedsQL 4.0 Short Form (SF-15) Total ScoreTime frame: Baseline, Weeks 2, 6, 8, and 10
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Florida
Gainesville, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.